Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines

• Main Authors: Haasis M.A., Ceria J.A., Kulpeng W., Teerawattananon Y., Alejandria M.
• Other Authors: SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
• Format: Article
• Published: Public Library of Science 2020
• Subjects: Pneumococcus conjugate vaccine 10; Pneumococcus vaccine; unclassified drug; 10-valent pneumococcal conjugate vaccine; 13-valent pneumococcal vaccine; vaccine; Article; cohort analysis; cost effectiveness analysis; cost utility analysis; drug cost; drug efficacy; economic evaluation; government; health care access; health care cost; health care delivery; herd immunity; human; Philippines; pneumococcal infection; preventive health service; program sustainability; quality adjusted life year; statistical model; adolescent; adult; aged; child; cost benefit analysis; drug effects; economics; female; financial management; immunology; income; infant; male; Markov chain; microbiology; middle aged; newborn; Pneumonia, Pneumococcal; preschool child; Streptococcus pneumoniae; vaccination; Adolescent; Adult; Aged; Child; Child, Preschool; Cost-Benefit Analysis; Female; Financing, Government; Humans; Immunization Programs; Income; Infant; Infant, Newborn; Male; Markov Chains; Middle Aged; Pneumococcal Vaccines; Vaccination; Vaccines, Conjugate
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/165692
• Institution: National University of Singapore

10.1371/journal.pone.0131156